Literature DB >> 16799623

Liver stem cells and their implication in hepatocellular and cholangiocarcinoma.

T Roskams1.   

Abstract

In the liver, several cell types have the longevity that is needed to be the cell of origin of a cancer: hepatocytes, cholangiocytes and progenitor cells. The latter are located in the most peripheral branches of the biliary tree, the ductules and canals of Hering. The most important risk factors for liver cancer are chronic viral hepatitis B and C and alcoholic and non-alcoholic steatohepatitis. In these and other chronic liver diseases, progenitor cell activation is seen, rendering them a target cell population for carcinogenesis. The degree of activation is positively correlated with the inflammatory activity and the stage of the disease. Recently, it has been shown that in the cirrhotic stage of most chronic liver diseases, the hepatocytes become senescent owing to telomere shortening. This makes it even more plausible that at least part of the hepatocellular carcinomas originate from a progenitor cell. Hepatocellular carcinomas expressing progenitor cell/ductular markers like cytokeratin 19 have a more aggressive clinical course. It is therefore important to recognize this entity.

Entities:  

Mesh:

Year:  2006        PMID: 16799623     DOI: 10.1038/sj.onc.1209558

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  144 in total

1.  pIgR: frenemy of inflammation, EMT, and HCC progression.

Authors:  Nathalie Sphyris; Sendurai A Mani
Journal:  J Natl Cancer Inst       Date:  2011-10-24       Impact factor: 13.506

Review 2.  The biliary tree--a reservoir of multipotent stem cells.

Authors:  Vincenzo Cardinale; Yunfang Wang; Guido Carpino; Gemma Mendel; Gianfranco Alpini; Eugenio Gaudio; Lola M Reid; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-28       Impact factor: 46.802

3.  Multiple cells of origin in cholangiocarcinoma underlie biological, epidemiological and clinical heterogeneity.

Authors:  Vincenzo Cardinale; Guido Carpino; Lola Reid; Eugenio Gaudio; Domenico Alvaro
Journal:  World J Gastrointest Oncol       Date:  2012-05-15

4.  Hybrid Periportal Hepatocytes Regenerate the Injured Liver without Giving Rise to Cancer.

Authors:  Joan Font-Burgada; Shabnam Shalapour; Suvasini Ramaswamy; Brian Hsueh; David Rossell; Atsushi Umemura; Koji Taniguchi; Hayato Nakagawa; Mark A Valasek; Li Ye; Janel L Kopp; Maike Sander; Hannah Carter; Karl Deisseroth; Inder M Verma; Michael Karin
Journal:  Cell       Date:  2015-08-13       Impact factor: 41.582

5.  Liver-specific knockout of GRP94 in mice disrupts cell adhesion, activates liver progenitor cells, and accelerates liver tumorigenesis.

Authors:  Wan-Ting Chen; Chun-Chih Tseng; Kyle Pfaffenbach; Gary Kanel; Biquan Luo; Bangyan L Stiles; Amy S Lee
Journal:  Hepatology       Date:  2014-01-27       Impact factor: 17.425

Review 6.  Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad.

Authors:  Kari Nichole Nejak-Bowen; Satdarshan P S Monga
Journal:  Semin Cancer Biol       Date:  2010-12-21       Impact factor: 15.707

Review 7.  Cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Lancet       Date:  2014-02-26       Impact factor: 79.321

8.  Nuclear beta-catenin induces an early liver progenitor phenotype in hepatocellular carcinoma and promotes tumor recurrence.

Authors:  Gudrun Zulehner; Mario Mikula; Doris Schneller; Franziska van Zijl; Heidemarie Huber; Wolfgang Sieghart; Bettina Grasl-Kraupp; Thomas Waldhör; Markus Peck-Radosavljevic; Hartmut Beug; Wolfgang Mikulits
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

Review 9.  The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology.

Authors:  Stephen Caldwell; Sang H Park
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

Review 10.  Wnt signaling in liver cancer.

Authors:  Yutaka Takigawa; Anthony M C Brown
Journal:  Curr Drug Targets       Date:  2008-11       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.